Molecules evolved
in nature

ATYR1940 FIRST SAFETY EXTENSION (005) TRIAL: PHASE 1B/2

In the third quarter of 2015, we initiated a long-term extension study for patients from our 002 Study. This multinational, multi-center, open-label extension study is designed to assess the long-term safety, effects on muscle, pharmacodynamic (PD) and systemic exposure of ATYR1940 in adult FSHD patients from our 002 Study. Eligible patients in jurisdictions where this trial is approved have the opportunity to receive weekly doses of 3.0 mg/kg until ATYR1940 receives regulatory approval or the program is discontinued.

We announced results from these patients in the fourth quarter 2016.

Data Release
 
Clinicaltrials.gov

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy